Regulatory Challenges, Reimbursement, and Risk-Benefit Assessment

被引：14
|
作者：
Breckenridge, A. [1 ]
机构：
[1] Med & Healthcare Prod Regulatory Agcy, London, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 88卷 / 02期
关键词：
D O I：
10.1038/clpt.2010.76
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [41] Clinical risk-benefit assessment of dopamine agonists
    Moeller, J. C.
    Eggert, K. M.
    Unger, M.
    Odin, P.
    Chaudhuri, K. R.
    Oertel, W. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 15 - 23
  • [42] A risk-benefit assessment of HIV protease inhibitors
    Moyle, GJ
    Gazzard, BG
    DRUG SAFETY, 1999, 20 (04) : 299 - 321
  • [43] A Risk-Benefit Assessment of Corticosteroids in the Management of Croup
    Robert W. Yates
    Iolo J. M. Doull
    Drug Safety, 1997, 16 : 48 - 55
  • [44] A risk-benefit assessment of oxytocics in obstetric practice
    Winkler, M
    Rath, W
    DRUG SAFETY, 1999, 20 (04) : 323 - 345
  • [45] A Risk-Benefit Assessment of HIV Protease Inhibitors
    Graeme J. Moyle
    Brian G. Gazzard
    Drug Safety, 1999, 20 : 299 - 321
  • [46] A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly
    Aart Jan van der Lely
    Wouter W. de Herder
    Steven W. J. Lamberts
    Drug Safety, 1997, 17 : 317 - 324
  • [47] A risk-benefit assessment of therapies for premature labour
    Higby, K
    Suiter, CR
    DRUG SAFETY, 1999, 21 (01) : 35 - 56
  • [48] A Risk-Benefit Assessment of Irinotecan in Solid Tumours
    Lillian L. Siu
    Eric K. Rowinsky
    Drug Safety, 1998, 18 : 395 - 417
  • [49] RISK-BENEFIT
    MARTIN, J
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1979, 174 (07) : 691 - 691
  • [50] A risk-benefit assessment of sulpiride in the treatment of schizophrenia
    Mauri, MC
    Bravin, S
    Bitetto, A
    Rudelli, R
    Invernizzi, G
    DRUG SAFETY, 1996, 14 (05) : 288 - 298
12345